Tapentadol: An initial analysis

Eric E. Prommer

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Tapentadol hydrochloride (17(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2- methyl-propyl)-phenol) is a newly released analgesic that works at two levels: by acting as a μ-opioid agonist and as a modulator of descending inhibitory pathways through its effects on neurotransmitters involved in these pathways. The theoretical advantage is the provision of synergistic analgesic activities, which may lessen the need for opioid escalation. The advantage is its potential as a possible new agent in neuropathic pain. Preclinical models confirm analgesic properties in acute pain and neuropathic pain models, but with less potency than morphine. Tapentadol has minimal CYP 450 interactions limiting potential for drug interactions. Human clinical trial data in nonmalignant pain suggest less potency than a step-3 opioid, and the drug remains to be tested in patients with cancer pain and neuropathic pain.

Original languageEnglish (US)
Pages (from-to)223-226
Number of pages4
JournalJournal of Opioid Management
Volume6
Issue number3
DOIs
StatePublished - May 2010

Fingerprint

Neuralgia
Opioid Analgesics
Analgesics
Acute Pain
Phenol
Drug Interactions
Morphine
Neurotransmitter Agents
Clinical Trials
Pain
Pharmaceutical Preparations
tapentadol

Keywords

  • Affinity
  • Neuropathic
  • Tapentadol

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Anesthesiology and Pain Medicine

Cite this

Tapentadol : An initial analysis. / Prommer, Eric E.

In: Journal of Opioid Management, Vol. 6, No. 3, 05.2010, p. 223-226.

Research output: Contribution to journalArticle

Prommer, Eric E. / Tapentadol : An initial analysis. In: Journal of Opioid Management. 2010 ; Vol. 6, No. 3. pp. 223-226.
@article{d8882a5c36e046b888603a688d9c9c39,
title = "Tapentadol: An initial analysis",
abstract = "Tapentadol hydrochloride (17(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2- methyl-propyl)-phenol) is a newly released analgesic that works at two levels: by acting as a μ-opioid agonist and as a modulator of descending inhibitory pathways through its effects on neurotransmitters involved in these pathways. The theoretical advantage is the provision of synergistic analgesic activities, which may lessen the need for opioid escalation. The advantage is its potential as a possible new agent in neuropathic pain. Preclinical models confirm analgesic properties in acute pain and neuropathic pain models, but with less potency than morphine. Tapentadol has minimal CYP 450 interactions limiting potential for drug interactions. Human clinical trial data in nonmalignant pain suggest less potency than a step-3 opioid, and the drug remains to be tested in patients with cancer pain and neuropathic pain.",
keywords = "Affinity, Neuropathic, Tapentadol",
author = "Prommer, {Eric E.}",
year = "2010",
month = "5",
doi = "10.5055/jom.2010.0020",
language = "English (US)",
volume = "6",
pages = "223--226",
journal = "Journal of Opioid Management",
issn = "1551-7489",
publisher = "Weston Medical Publishing",
number = "3",

}

TY - JOUR

T1 - Tapentadol

T2 - An initial analysis

AU - Prommer, Eric E.

PY - 2010/5

Y1 - 2010/5

N2 - Tapentadol hydrochloride (17(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2- methyl-propyl)-phenol) is a newly released analgesic that works at two levels: by acting as a μ-opioid agonist and as a modulator of descending inhibitory pathways through its effects on neurotransmitters involved in these pathways. The theoretical advantage is the provision of synergistic analgesic activities, which may lessen the need for opioid escalation. The advantage is its potential as a possible new agent in neuropathic pain. Preclinical models confirm analgesic properties in acute pain and neuropathic pain models, but with less potency than morphine. Tapentadol has minimal CYP 450 interactions limiting potential for drug interactions. Human clinical trial data in nonmalignant pain suggest less potency than a step-3 opioid, and the drug remains to be tested in patients with cancer pain and neuropathic pain.

AB - Tapentadol hydrochloride (17(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2- methyl-propyl)-phenol) is a newly released analgesic that works at two levels: by acting as a μ-opioid agonist and as a modulator of descending inhibitory pathways through its effects on neurotransmitters involved in these pathways. The theoretical advantage is the provision of synergistic analgesic activities, which may lessen the need for opioid escalation. The advantage is its potential as a possible new agent in neuropathic pain. Preclinical models confirm analgesic properties in acute pain and neuropathic pain models, but with less potency than morphine. Tapentadol has minimal CYP 450 interactions limiting potential for drug interactions. Human clinical trial data in nonmalignant pain suggest less potency than a step-3 opioid, and the drug remains to be tested in patients with cancer pain and neuropathic pain.

KW - Affinity

KW - Neuropathic

KW - Tapentadol

UR - http://www.scopus.com/inward/record.url?scp=77954617741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954617741&partnerID=8YFLogxK

U2 - 10.5055/jom.2010.0020

DO - 10.5055/jom.2010.0020

M3 - Article

C2 - 20642251

AN - SCOPUS:77954617741

VL - 6

SP - 223

EP - 226

JO - Journal of Opioid Management

JF - Journal of Opioid Management

SN - 1551-7489

IS - 3

ER -